Phase 2 Trial of AZD1775 for Squamous Cell Lung Cancer

Share this content:
AZD1775 is an inhibitor of the Wee1 kinase, which is linked to chemotherapy resistance.
AZD1775 is an inhibitor of the Wee1 kinase, which is linked to chemotherapy resistance.

Title: A Phase II Trial of AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer1

Principal Investigators: Jhanelle Gray, MD, H. Lee Moffitt Cancer Center and Research Institute

Description: For this single-group assignment phase 2 trial (ClinicalTrials.gov Identifier: NCT02513563), researchers are evaluating the safety and efficacy of AZD1775 with carboplatin and paclitaxel among patients with squamous cell lung cancer. AZD1775 is an inhibitor of the Wee1 kinase, which is linked to chemotherapy resistance.

All patients will receive 5 doses of combination carboplatin, paclitaxel, and AZD1775 over a 21-day cycle; treatment will be twice daily on days 1 and 2 and once on day 3.

Included patients will have advanced or metastatic disease without curative options. Prior chemotherapy, radiotherapy, checkpoint inhibition, or vaccine therapy is allowed.

For more study information, including inclusion and exclusion criteria, study locations, and contact information, visit https://clinicaltrials.gov/ct2/show/NCT02513563.

Status: This study is open and recruiting patients as of February 22, 2018.

This study is sponsored by the H. Lee Moffitt Cancer Center and Research Institute.

Reference

  1. Clinicaltrials.gov. AZD1775 plus carboplatin-paclitaxel in squamous cell lung cancer.  NCT02513563. https://clinicaltrials.gov/ct2/show/NCT02513563. Accessed February 22, 2018.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs